Incannex Healthcare Inc. has announced the successful completion of its RePOSA Phase 2 clinical trial database lock for IHL-42X, a drug candidate aimed at treating obstructive sleep apnoea (OSA). This milestone, achieved on June 16, 2025, enables the commencement of final statistical analysis. The top-line results of the trial are expected to be released in July 2025. The trial focuses on patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). IHL-42X is being developed as a fixed-dose combination therapy designed to reduce apnea episodes and improve sleep quality, aiming to provide an alternative to current treatments in a field where no approved oral pharmacological treatments currently exist.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.